<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002188</url>
  </required_header>
  <id_info>
    <org_study_id>271A</org_study_id>
    <secondary_id>L1057-28</secondary_id>
    <secondary_id>96ACR-LIG2</secondary_id>
    <nct_id>NCT00002188</nct_id>
  </id_info>
  <brief_title>A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma</brief_title>
  <official_title>Phase II Evaluation of Oral ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anderson Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ligand Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if ALRT1057 is safe and effective in treating patients&#xD;
      with AIDS-related Kaposi's sarcoma (KS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients receive open-label ALRT1057 for 16 weeks, as tolerated. In the absence of&#xD;
      unacceptable toxicity, patients may continue treatment indefinitely provided they continue to&#xD;
      benefit from therapy and the study remains open and active.&#xD;
&#xD;
      Thirteen patients are treated initially. If at least one response is observed in these&#xD;
      patients, up to 14 additional patients will be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>27</enrollment>
  <condition>Sarcoma, Kaposi</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alitretinoin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV positive status and histologic confirmation of KS.&#xD;
&#xD;
          -  CD4 count &gt; 200 mm3 (required of one-half of patients).&#xD;
&#xD;
          -  Minimum of 6 mucocutaneous KS lesions, including at least 3 raised lesions meeting&#xD;
             criteria for &quot;indicator&quot; lesions.&#xD;
&#xD;
          -  Acceptable organ system function.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
        Serious or intercurrent illness or infection that would interfere with the ability of the&#xD;
        patient to carry out the treatment program.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Systemic therapy for KS within 30 days.&#xD;
&#xD;
          -  Local or topical therapy for KS indicative lesions within 60 days.&#xD;
&#xD;
          -  Systemic therapy with vitamin A in doses exceeding 15,000 IU per day or other retinoid&#xD;
             class drug.&#xD;
&#xD;
        Required:&#xD;
&#xD;
        Approved antiretroviral therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 1997</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Sarcoma, Kaposi</keyword>
  <keyword>Antineoplastic Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alitretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

